NuGene International, Inc. has formed a new division to focus specifically on stem cell derived treatments that may require FDA approval. The company markets and sells a variety of cosmeceutical products based on adipose derived human stem cells and human stem cell media. NuGene has carefully developed its line of products based upon proprietary stem cell technology and intends to expand this into a line of FDA approved pharmaceuticals.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0144 USD | +2.86% |
|
+28.57% | +21.01% |
06/05 | Livento Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
01/04 | Livento Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+21.01% | 1.16Cr | |
+15.34% | 830.56Cr | |
-20.28% | 513.67Cr | |
+4.51% | 487.88Cr | |
+9.46% | 472.86Cr | |
+3.55% | 401.91Cr | |
+29.48% | 349.24Cr | |
-6.63% | 308.88Cr | |
-14.54% | 270.22Cr | |
-21.98% | 238.74Cr |
- Stock Market
- Equities
- NUGN Stock
- News Livento Group, Inc.
- NuGene Forms a New Division to Focus Specifically on Stem Cell Derived Treatments